Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care

Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care

Da: GRACEcast
0 0 5 anni fa
Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?

Seguici su Facebook